These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 30988147)
21. Comparison of ß-lactam plus aminoglycoside versus ß-lactam plus fluoroquinolone empirical therapy in serious nosocomial infections due to Gram-negative bacilli. Ereshefsky BJ; Al-Hasan MN; Gokun Y; Martin CA J Chemother; 2017 Feb; 29(1):30-37. PubMed ID: 27376664 [TBL] [Abstract][Full Text] [Related]
22. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Bliziotis IA; Samonis G; Vardakas KZ; Chrysanthopoulou S; Falagas ME Clin Infect Dis; 2005 Jul; 41(2):149-58. PubMed ID: 15983909 [TBL] [Abstract][Full Text] [Related]
23. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms. Sharma R; Park TE; Moy S Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862 [TBL] [Abstract][Full Text] [Related]
24. Meta-analysis: randomized controlled trials of clindamycin/aminoglycoside vs. beta-lactam monotherapy for the treatment of intra-abdominal infections. Falagas ME; Matthaiou DK; Karveli EA; Peppas G Aliment Pharmacol Ther; 2007 Mar; 25(5):537-56. PubMed ID: 17305755 [TBL] [Abstract][Full Text] [Related]
25. [A comparative review of combination therapy: 2 beta-lactams versus beta-lactam plus aminoglycoside]. Dejace P; Klastersky J Infection; 1987; 15 Suppl 4():S158-67. PubMed ID: 3312028 [TBL] [Abstract][Full Text] [Related]
26. Is intrathecal or intraventricular therapy with polymyxins or aminoglycosides still needed to improve the outcome of post-neurosurgical extensively/multidrug-resistant Gram-negative bacteria-related meningitis/ventriculitis in the current era of novel beta-lactams and beta-lactam/beta-lactamase inhibitor combinations? Gatti M; Virgili G; Viale P; Pea F Int J Antimicrob Agents; 2024 Jun; 63(6):107177. PubMed ID: 38643849 [No Abstract] [Full Text] [Related]
27. Clinical implications of β-lactam-aminoglycoside synergism: systematic review of randomised trials. Marcus R; Paul M; Elphick H; Leibovici L Int J Antimicrob Agents; 2011 Jun; 37(6):491-503. PubMed ID: 21292449 [TBL] [Abstract][Full Text] [Related]
28. Comparison of empiric aztreonam and aminoglycoside regimens in the treatment of serious gram-negative lower respiratory infections. Bjornson HS; Ramirez-Ronda C; Saavedra S; Rivera-Vázquez CR; Liu C; Hinthorn DR Clin Ther; 1993; 15(1):65-78. PubMed ID: 8458056 [TBL] [Abstract][Full Text] [Related]
29. Newer β-Lactam/β-Lactamase inhibitor for multidrug-resistant gram-negative infections: Challenges, implications and surveillance strategy for India. Veeraraghavan B; Pragasam AK; Bakthavatchalam YD; Anandan S; Ramasubramanian V; Swaminathan S; Gopalakrishnan R; Soman R; Abraham OC; Ohri VC; Walia K Indian J Med Microbiol; 2018; 36(3):334-343. PubMed ID: 30429384 [TBL] [Abstract][Full Text] [Related]
30. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Paul M; Soares-Weiser K; Leibovici L BMJ; 2003 May; 326(7399):1111. PubMed ID: 12763980 [TBL] [Abstract][Full Text] [Related]
32. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections. Eljaaly K; Alharbi A; Alshehri S; Ortwine JK; Pogue JM Drugs; 2019 Feb; 79(3):243-269. PubMed ID: 30723876 [TBL] [Abstract][Full Text] [Related]
33. Aminoglycoside resistance rates, phenotypes, and mechanisms of Gram-negative bacteria from infected patients in upper Egypt. Gad GF; Mohamed HA; Ashour HM PLoS One; 2011 Feb; 6(2):e17224. PubMed ID: 21359143 [TBL] [Abstract][Full Text] [Related]
34. Combination therapy for treatment of infections with gram-negative bacteria. Tamma PD; Cosgrove SE; Maragakis LL Clin Microbiol Rev; 2012 Jul; 25(3):450-70. PubMed ID: 22763634 [TBL] [Abstract][Full Text] [Related]
35. [New Antibiotics for Treatment of Highly Resistant Gram-negative Bacteria]. Probst-Kepper M; Geginat G Anasthesiol Intensivmed Notfallmed Schmerzther; 2018 Jul; 53(7-08):529-542. PubMed ID: 30036899 [TBL] [Abstract][Full Text] [Related]
36. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Martínez JA; Cobos-Trigueros N; Soriano A; Almela M; Ortega M; Marco F; Pitart C; Sterzik H; Lopez J; Mensa J Antimicrob Agents Chemother; 2010 Sep; 54(9):3590-6. PubMed ID: 20585123 [TBL] [Abstract][Full Text] [Related]
37. Current guidelines for the treatment of severe pneumonia and sepsis. Bodmann KF Chemotherapy; 2005 Aug; 51(5):227-33. PubMed ID: 16103664 [TBL] [Abstract][Full Text] [Related]
38. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Bush K Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989 [TBL] [Abstract][Full Text] [Related]